Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and BeOne Medicines (ONC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Amgen (AMGN – Research Report) and BeOne Medicines (ONC – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Amgen (AMGN)
In a report released today, Matt Phipps from William Blair maintained a Buy rating on Amgen. The company’s shares closed last Tuesday at $338.59, close to its 52-week high of $346.85.
According to TipRanks.com, Phipps is a 4-star analyst with an average return of
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $355.38, representing a 4.1% upside. In a report issued on January 22, DBS also maintained a Buy rating on the stock with a $400.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
BeOne Medicines (ONC)
In a report released today, Etzer Darout from Barclays maintained a Buy rating on BeOne Medicines, with a price target of $394.00. The company’s shares closed last Tuesday at $346.38.
According to TipRanks.com, Darout is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BeOne Medicines with a $406.33 average price target, representing a 18.7% upside. In a report issued on January 29, RBC Capital also maintained a Buy rating on the stock with a $417.00 price target.
